Juno will pay $24M to settle the JCAR015 scandal — but don’t expect that to change industry attitudes on reporting snafus
A notorious string of patient deaths caused by Juno Therapeutics’ JCAR015 wound up killing the one-time CAR-T star, derailing their shot at joining the breakthrough race eventually won by Novartis and Kite. Throughout the controversy, though, Juno execs fiercely maintained that they had done everything by the book.
They never budged an inch. Until now.
The company, now a subsidiary of Celgene, as well as former CEO Hans Bishop, have signed off on a $24 million payment to the stockholders who brought a class action suit against the biotech based on their claims that the company had misled investors by concealing the death of the first patient.
This article is for premium subscribers only
Upgrade to a premium subscription plan for unlimited access, and join our community of key biopharma players.